The research group Neuronal Signalling Unit of the Lleida Biomedical Research Institute (IRBLleida) and the University of Lleida (UdL) has made important progress in establishing a new strategy in the therapeutic treatment of spinal muscular atrophy, a disorder that leads to weakness and progressive muscle atrophy, and represents the most common lethal genetic disease in babies. His research demonstrates the beneficial effect of the inhibition of calpain, an enzyme that breaks down proteins into smaller units and that is implicated in neuronal injury, neurodegenerative disorders, and neuronal aging processes, in the treatment of spinal muscular atrophy. The research, which has been carried out in animal models (with mice) and also with human cells, has recently been published in the journal Cell Death & Disease.
Reference articles:
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del...
Theriva™ Biologics has announced the presentation of preclinical da...
Biotechnology portal in Spain
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Biotech-Spain.com - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory